BTAI · BioXcel Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on BTAI. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About BTAI · BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Live Quote
SELL (score -3) · 12-1 mom -34.1% · RSI 57.4 · above_50_only · -81.5% from high
Targets blend Wall Street consensus (4 analysts: low $1.00 / mean $14.00 / high $38.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The investigation triggered on a Form 4 cluster (8 filings in ~14 days), but ALL transactions are code M (RSU vesting) or S (10b5-1 plan sales to cover taxes) — zero open-market P purchases from any insider. The trigger condition was not met. The business is deeply distressed: $17M cash vs. $100M debt, burning ~$34M/year in FCF, no approved revenue-generating drug except IGALMI (hospital-only use), and it just raised only $7.8M gross in March 2026 via dilutive equity — signaling acute capital stress. There is a legitimate catalyst: November 14, 2026 PDUFA for IGALMI at-home expansion, with positive SERENITY Phase 3 data presented May 28, 2026. But no smart-money buy conviction exists to back it.